5 completed, 4 terminated. 9 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 5, Terminated 4 |
| Phase 2 | 4 | Completed 3, Terminated 1 |
Follow Stage I Chronic Lymphocytic Leukemia: new trials by email Literature Review of Stage I Chronic Lymphocytic Leukemia trials Research Report on Stage I Chronic Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 55 | 2014-07-29 | 2026-03-11 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia alemtuzumab, rituximab, PGG beta-glucan - B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Mayo Clinic | 22 | 2011-01-01 | 2020-06-23 |
| Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Alvocidib Hydrochloride, Cyclophosphamide, Diagnostic Laboratory Biomarker Analysis - Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 9 | 2010-04-01 | 2015-11-11 |
| Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Fludarabine Phosphate, Cyclophosphamide, Rituximab - Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 40 | 2009-06-01 | 2020-02-25 |
| Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia obatoclax mesylate, fludarabine phosphate, rituximab - B-cell Chronic Lymphocytic Leukemia, Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 28 | 2008-01-01 | 2013-09-30 |
| Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma alvocidib, pharmacological study, laboratory biomarker analysis - B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Small Lymphocytic Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 24 | 2006-09-01 | 2013-07-02 |
| Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma fenretinide, rituximab - Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 32 | 2005-10-01 | 2014-10-06 |
| Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma alvocidib, fludarabine phosphate, rituximab - B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Grade 1 Follicular Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 37 | 2003-04-01 | 2013-06-04 |
Leukemia, Lymphocytic, Chronic, B-Cell (9) · Lymphoma, B-Cell, Marginal Zone (4) · Lymphoma, Follicular (4) · Lymphoma, Mantle-Cell (4) · Waldenstrom Macroglobulinemia (4) · Hodgkin Disease (3) · Leukemia, Prolymphocytic (3) · Lymphoma, Large B-Cell, Diffuse (3) · Burkitt Lymphoma (2) · Leukemia, Hairy Cell (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Congenital Abnormalities (1) · Cytomegalovirus Infections (1) · Intraocular Lymphoma (1) · Leukemia (1)
Chronic Disease (9) · Disease Attributes (9) · Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Leukemia, B-Cell (9) · Leukemia, Lymphoid (9) · Lymphatic Diseases (9) · Lymphoproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Leukemia (8)
Rituximab (7) · Cyclophosphamide (3) · alvocidib (3) · fludarabine phosphate (3) · Alemtuzumab (1) · Amplified Fragment Length Polymorphism Analysis (1) · Doxorubicin (1) · Etoposide (1) · Fenretinide (1) · Flow Cytometry (1) · In Situ Hybridization, Fluorescence (1) · Lenalidomide (1) · Polymerase Chain Reaction (1) · Prednisone (1) · Vincristine (1)
National Cancer Institute (NCI) (5) · City of Hope Medical Center (1) · Fred Hutchinson Cancer Center (1) · Mayo Clinic (1) · University of Chicago (1)
United States (9)
Ajay Gopal (1) · Jennifer Brown (1) · John Byrd (1) · Joseph Flynn (1) · Leslie Andritsos (1) · Mazyar Shadman (1) · Ryotaro Nakamura (1) · Sonali Smith (1) · Steven Ansell, M.D. (1)
PMID 26853648, PMID 27118540, PMID 30562587, PMID 40720747
U01CA076576 (3), P30CA014599 (1), P30CA015704 (1), P30CA016058 (1), R21CA119519 (1), U01CA062490 (1)